Addus HomeCare Corporation (ADUS)vsAstraZeneca PLC (AZN)
ADUS
Addus HomeCare Corporation
$96.89
-0.07%
HEALTHCARE · Cap: $1.81B
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4029% more annual revenue ($58.74B vs $1.42B). AZN leads profitability with a 17.4% profit margin vs 6.7%. ADUS appears more attractively valued with a PEG of 0.96. ADUS earns a higher WallStSmart Score of 70/100 (B).
ADUS
Strong Buy70
out of 100
Grade: B
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.9%
Fair Value
$152.11
Current Price
$96.89
$55.22 discount
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 52.1% YoY
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 25.6% year-over-year
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.7% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADUS
The strongest argument for ADUS centers on EPS Growth, Altman Z-Score, PEG Ratio. Revenue growth of 25.6% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : ADUS
The primary concerns for ADUS are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
ADUS profiles as a growth stock while AZN is a value play — different risk/reward profiles.
ADUS carries more volatility with a beta of 0.96 — expect wider price swings.
ADUS is growing revenue faster at 25.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
ADUS scores higher overall (70/100 vs 64/100) and 25.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Addus HomeCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?